Skip to main content

Table 1 Characteristics of sixty breast cancer patients treated with neoadjuvant docetaxel plus epirubicin.

From: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

Age

  

Characteristcs

n = 60 (range)

%

Median

50 (29 – 67)

 

≤ 45 years

18

30

>45 years

42

70

Menopausal status

  

Pre

28

46.6

Post

32

53.4

Chemotherapy cycles (median)

3 (2 – 5)

 

Clinical Stage

  

IIA

12

20

IIB

19

31.7

IIIA

8

13.3

IIIB

18

30

IIIC

3

5

Histology

  

Ductal

49

81.7

Lobular

4

6.7

Medular

4

6.7

Outhers

3

5

Histologic grade

  

I

16

26.7

II

32

53.3

III

11

18.4

ER

  

Positive

45

75

Negative

15

25

PR

  

Positive

32

53.3

Negative

28

46.7

P53 protein

  

Positive

17

28.3

Negative

43

71.7

P21 protein

  

Positive

20

33.3

Negative

40

66.7

HER-2

  

Positive

11

18.3

Negative

49

81.7

  1. N = number of patients; ER = estrogen receptor; PR = progesterone receptor.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us